Nat Rev Neurol:深脑刺激有助于强迫症等疾病新疗法的开发

2019-04-13 不详 细胞

发表在《Nature Reviews Neurology》上的一篇新论文表明,帕金森病深部脑刺激(DBS)的最新进展可能有助于治疗强迫症(OCD),Gilles de la Tourette综合征和抑郁症等疾病。

发表在《Nature Reviews Neurology》上的一篇新论文表明,帕金森病深部脑刺激(DBS)的最新进展可能有助于治疗强迫症(OCD),Gilles de la Tourette综合征和抑郁症等疾病。

其他“双向脑 - 计算机接口(BCI)”近年来一直在开发中,特别是用于神经元活动的实时信号处理,以允许瘫痪患者直接通过大脑控制机器人手臂。

“有趣的是,深脑刺激研究人员往往是神经学家或神经外科医生,而脑机接口研究人员通常是神经科学家,机器人专家和工程师。通过合作和分享信息,我们可以相互学习,并可能扩大这项技术的范围,以便它可以帮助更多的人。“

DBS通常用于缓解与帕金森病相关的摇晃和僵硬。尽管已经在40多种其他脑部目标中进行了试验,但已经建立了很少的其他疾病适应症。最新的闭环DBS系统感知刺激后大脑的变化,并相应地自动调整下一个刺激脉冲的水平。这种对刺激传递方式的调整允许定制的,准确的治疗,其可以证明适合于其他病症。

可能受益于闭环DBS的其他领域包括强迫症 - 尽管早期试验表明在改善之前可能存在时间延迟,Gilles de la Tourette综合征 - 用于治疗运动抽搐和精神症状以及抑郁症 - 尽管早期试验表明电极的确切位置和刺激参数是关键的。

具有传感功能的神经刺激器仍处于起步阶段。它们仍然只用于研究环境,因此闭环DBS尚不是帕金森病或任何其他疾病的长期治疗方案。然而,这些新系统很快就会上市,当他们这样做时,他们将带来新的治疗可能性和新的希望。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883671, encodeId=2dc318836e161, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 29 18:35:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000752, encodeId=ccc32000e52f5, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 23 21:35:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457669, encodeId=8a53145e669df, content=<a href='/topic/show?id=f9f684e27d6' target=_blank style='color:#2F92EE;'>#脑刺激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84727, encryptionId=f9f684e27d6, topicName=脑刺激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd4c5968615, createdName=amyloid, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554556, encodeId=168f1554556b6, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2020-02-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883671, encodeId=2dc318836e161, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 29 18:35:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000752, encodeId=ccc32000e52f5, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 23 21:35:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457669, encodeId=8a53145e669df, content=<a href='/topic/show?id=f9f684e27d6' target=_blank style='color:#2F92EE;'>#脑刺激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84727, encryptionId=f9f684e27d6, topicName=脑刺激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd4c5968615, createdName=amyloid, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554556, encodeId=168f1554556b6, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-23 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883671, encodeId=2dc318836e161, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 29 18:35:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000752, encodeId=ccc32000e52f5, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 23 21:35:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457669, encodeId=8a53145e669df, content=<a href='/topic/show?id=f9f684e27d6' target=_blank style='color:#2F92EE;'>#脑刺激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84727, encryptionId=f9f684e27d6, topicName=脑刺激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd4c5968615, createdName=amyloid, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554556, encodeId=168f1554556b6, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883671, encodeId=2dc318836e161, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 29 18:35:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000752, encodeId=ccc32000e52f5, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 23 21:35:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457669, encodeId=8a53145e669df, content=<a href='/topic/show?id=f9f684e27d6' target=_blank style='color:#2F92EE;'>#脑刺激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84727, encryptionId=f9f684e27d6, topicName=脑刺激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd4c5968615, createdName=amyloid, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554556, encodeId=168f1554556b6, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Apr 15 10:35:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 kcb074

相关资讯

第14届阿尔茨海默症和帕金森国际会议:Aptinyx将介绍NYX-458的临床前数据

Aptinyx是一家临床阶段的生物制药公司,开发用于治疗大脑和神经系统疾病的变革疗法,近日宣布即将在第14届阿尔茨海默症和帕金森国际会议上发表演讲,重点介绍其新型NMDA受体调节剂NYX-458的临床前数据

AGING CELL:心磷脂重塑联系线粒体功能障碍与帕金森病

心磷脂(CL)是线粒体特征性磷脂,其是膜结构,呼吸,动力学和线粒体自噬所必需的。活性氧对CL的氧化损伤与帕金森病(PD)的发病机制有关,但至今为止,其根本原因仍然难以捉摸。

帕金森运动症状治疗的新方法:鞘内注射仙人掌毒素

帕金森病(PD)是一种慢性神经退行性疾病,其特征在于运动症状,例如运动迟缓、静止性震颤、姿势紊乱和僵硬。许多临床和病理学研究表明,PD病变能够延伸到黑质以外,并且涉及非多巴胺能神经递质系统,其能够介导运动和非运动症状。Sorrento Therapeutics公司近日宣布,仙人掌毒素(Resiniferatoxin,RTX)能够控制PD的运动症状。

第14届阿尔茨海默症和帕金森国际会议:Eisai将公布其一系列在研药物的临床试验结果

Eisai公司近日宣布,将于3月26日举行的第14届阿尔茨海默症和帕金森国际会议上公布其一系列在研药物的临床试验结果:BAN2401,一种抗淀粉样蛋白β(Aβ)初原纤维抗体,正在进行III期试验;elenbecestat,一种口服选择性BACE1抑制剂,目前正在进行两项III期研究(MISSION AD1 / 2)。

从斑马鱼身上竟然获得治疗帕金森的方法!

与哺乳动物相比,成年斑马鱼会使大脑中的神经元再生,但这种能力的程度和变异性尚不清楚。来自Edinburgh大学脑神经科学研究中心的Thomas Becker及其研究团队探寻了各种多巴胺能神经元群体的丧失是否足以触发神经元的功能性再生。他们的研究结果为未来治疗具有运动异常、震颤等症状的神经系统疾病提供了新的思路。研究人员分析了斑马鱼两种性别的遗传谱系,其示踪显示特定的间脑室间室 - 放射状神经胶质祖

实验性帕金森疗法显示出巨大前景

布里斯托大学的研究表明,一种新型实验药物很可能恢复帕金森病患者受损的脑细胞。